GC Biopharma Validates MAV/06 Varicella Strain with 30-Year Data Review
GC Biopharma has published a landmark review paper detailing three decades of clinical and real-world data for its proprietary MAV/06 varicella vaccine strain. The publication underscores the strain's long-term safety and efficacy, positioning it as a primary global alternative to the widely used Oka strain.